Pharma BD Deal Intelligence
SERB picked up European and MENA rights to IDEFIRIX, a first-in-class IgG-cleaving enzyme conditionally authorized since 2020, for €115M (~$128M) — a regional carve-out that lets Hansa keep its US optionality ahead of the December 19, 2026 PDUFA date.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Hansa Biopharma signed a EUR 115 million imlifidase licensing agreement with SERB Pharmaceuticals for European and MENA rights. The deal preserves Hansa's…
Hansa Biopharma has signed an Idefirix licensing deal with SERB Pharmaceuticals worth up to EUR 115 million, covering exclusive rights to develop and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Hansa Biopharma granted SERB Pharmaceuticals exclusive rights to develop and commercialize IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA for total consideration of €115M (~$128M USD). IDEFIRIX is the first-in-class IgG-cleaving enzyme conditionally authorized in Europe for desensitization of highly sensitized kidney transplant patients with positive crossmatch.
8K US cases/yr · $128M Deal value €115M (~$128M USD) for EU/UK/EEA/MENA rights, Hansa Biopharma
Highly sensitized kidney transplant candidates (cPRA >80-98%) have circulating anti-HLA IgG antibodies that cause positive crossmatch against most deceased donors, leading to multi-year waitlist times, higher mortality, and limited transplant access. Imlifidase cleaves IgG within hours to convert positive crossmatches to negative, enabling deceased-donor transplant in a population otherwise stranded on dialysis.
Imlifidase is the only IgG-cleaving enzyme approved for kidney desensitization. Standard-of-care alternatives include IVIG, plasmapheresis, and rituximab-based regimens (off-label, days-to-weeks onset). Competitive threats include CSL's clazakizumab (IL-6 antibody, late-stage AMR program) and emerging FcRn blockers (efgartigimod, rozanolixizumab) being explored in transplant. SERB takes a focused critical-care/rare-disease franchise that fits its existing hospital specialty channel.
At announcement, completion was expected within ~60 days, subject to customary closing conditions including foreign direct investment (FDI) regulatory approval. As of 2026-06-07 no closing has been announced; deal remains Pending.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| SERB Pharmaceuticals SA / Hansa Biopharma AB (this deal) | 2026 | $134M | — |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Novartis AG / Regulus Therapeutics | 2025 | $1.7B | 62 |
| Eli Lilly and Company / Ascidian Therapeutics, Inc. | 2026 | $1.9B | 62 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
← Browse all deals · How we score deals
More: 2026 deals · Nephrology deals